Ramos M, Rodríguez-Flores GV, Pérez-Jacobo F

Language: Spanish
References: 13
Page: 44-49
PDF size: 251.80 Kb.

ABSTRACT

Background: Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare entity, characterized by diffuse infiltration CD30-positive cells with anaplastic morphology. Its treatment is localized in cases of solitary or grouped lesions and systemic for multifocal disease or for those with regional node involvement. Currently, brentuximab-vedotin is the preferred option in this setting.
Clinical cases: Clinical case 1: 67-year-old male with C-ALCL and regional node involvement (N1), without response to chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone; he received brentuximab-vedotin monotherapy as second-line treatment regimen. Clinical case 2: 60-year-old male diagnosed with C-ALCL, multifocal lesions and no response to two previous lines of chemotherapy who achieved complete response after treatment with brentuximab-vedotin.
Conclusiones: C-ALCL is an under-reported entity in our country; and with limited data on the use of brentuximab-vedotin-based immunotherapy or immunochemotherapy, such as those presented in these clinical cases. Brentuximab-vedotin should be considered a therapeutic option according to response rates reported in the literature, as well as that shown in case reports such as the present work.

REFERENCES

1. Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med 2017; 37 (3): 527-546. doi. 10.1016/j.cll.2017.06.006.

2. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol 2017; 10 (3): 239-249. doi. 10.1080/17474086.2017.1281122.

3. Fiore D, Cappelli LV, Broccoli A, Zinzani PL, et al. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer 2020; 20 (6): 323-342.

4. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, et al. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020; 18 (5): 522-536. doi. 10.6004/jnccn.2020.0022.

5. Alaibac M. Monoclonal antibodies against cutaneous T-cell lymphomas. Expert Opin Biol Ther. 2017; 17 (12): 1503- 1510. doi. 10.1080/14712598.2017.1369951.

6. Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood 2017; 129 (9): 1103-1112. doi. 10.1182/blood-2016-08-692566.

7. Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Rev H emato l2019; 12 (1):5-19. doi. 10.1080/17474086.2019.1558399.

8. Gisselbrecht C, Sibon D. New perspectives in the therapeutic approach of peripheral T-cell lymphoma. Curr Opin Oncol 2018; 30 (5): 285-291. doi. 10.1097/ CCO.0000000000000469.

9. Horwitz S, O’Connor OA, Pro B, Illidge T, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019 393 (10168): 229-240. doi. 10.1016/S0140-6736(18)32984-2.

10. Prince HM, Kim YH, Horwitz SM, Dummer R, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390 (10094): 555-566. doi. 10.1016/S0140- 6736(17)31266-7.

11. Ruiz-Arriaga LF, Landgrave-Gómez I, Toussaint-Caire S, Lacy- Niebla RM, et al. Linfoma anaplásico de células T grandes primario cutáneo CD30+. Serie de nueve casos. Gac Med Mex 2019; 155 (2): 130-135.

12. González KIG, Pérez DA, Bojórquez AM, González ST. Epidemiología de linfoma cutáneo en el Servicio de Dermatooncología del Centro Dermatológico “Pascua”: Experiencia de 20 años. Dermatol CMQ 2008; 6 (4): 221-226.

13. Yu JB, Blitzblau RC, Decker RH, Housman DM, et al. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2008; 26 (9): 1483-8. doi. 10.1200/JCO.2007.14.1374.